Mikiya Ishihara

762 total citations
35 papers, 234 citations indexed

About

Mikiya Ishihara is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mikiya Ishihara has authored 35 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mikiya Ishihara's work include Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Mikiya Ishihara is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (11 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Mikiya Ishihara collaborates with scholars based in Japan, United States and France. Mikiya Ishihara's co-authors include Hiroshi Shiku, Yoshihiro Miyahara, Hirofumi Mukai, Toshiro Mizuno, Shunji Nagai, Hiroaki Ikeda, Keiji Nihei, Naoyuki Katayama, Noriaki Wada and Shinichi Kageyama and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mikiya Ishihara

26 papers receiving 232 citations

Peers

Countries citing papers authored by Mikiya Ishihara

Since Specialization

Citations

This map shows the geographic impact of Mikiya Ishihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikiya Ishihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikiya Ishihara more than expected).

Fields of papers citing papers by Mikiya Ishihara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikiya Ishihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikiya Ishihara. The network helps show where Mikiya Ishihara may publish in the future.

Co-authorship network of co-authors of Mikiya Ishihara

This figure shows the co-authorship network connecting the top 25 collaborators of Mikiya Ishihara. A scholar is included among the top collaborators of Mikiya Ishihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikiya Ishihara. Mikiya Ishihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of MAGE‐A4 expression in breast cancer and its impact on prognosis 2024 ·Cancer Science ·(unknown), Kanako Saito, (unknown), Yuji Kozuka, (unknown), Yuki Nishimura, Makoto Ishitobi, Mikiya Ishihara, Toshiro Mizuno, Isao Tawara, (unknown), Tomoko Ogawa, (unknown), Yoshihiro Miyahara	0
2	Long-Term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-Positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 Strategy 2024 ·Oncology ·(unknown), Nobuyoshi Kittaka, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jun Okuno, (unknown), Saki Matsui, Mikiya Ishihara, (unknown), Keiichiro Honma, Takahiro Nakayama	0
3	Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316) 2023 ·Breast Cancer ·Manabu Futamura, Takahiro Nakayama, Tetsuhiro Yoshinami, (unknown), Mikiya Ishihara, (unknown), (unknown), (unknown), (unknown), Masafumi Shimoda, (unknown), (unknown), Hiroyuki Yasojima, (unknown), Yoshihisa Tokumaru, Norikazu Masuda	2
4	Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial 2023 ·Clinical Cancer Research ·Akira Kawai, Mikiya Ishihara, Tomoki Nakamura, Shigehisa Kitano, Shintaro Iwata, Kohichi Takada, Makoto Emori, Koji Kato, Makoto Endo, Yoshihiro Matsumoto, Shigeki Kakunaga, (unknown), Yoshihiro Miyahara, (unknown), Shinya Tanaka, (unknown), (unknown), Akihiko Matsumine, Shinichi Kageyama, Takafumi Ueda	10
5	Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report 2023 ·Anticancer Research ·Kunihiro Asanuma, Mikiya Ishihara, Tomoki Nakamura, (unknown), (unknown), Shinichi Kageyama, Hiroshi Shiku, Akihiro Sudo	0
6	αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence 2023 ·iScience ·Mikiya Ishihara, Hiroshi Miwa, Hiroshi Fujiwara, Yasushi Akahori, Takuma Kato, Yoshimasa Tanaka, Isao Tawara, Hiroshi Shiku	4
7	Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer 2023 ·Anticancer Research ·(unknown), Kanako Saito, Yuji Kozuka, (unknown), (unknown), Makoto Ishitobi, Mikiya Ishihara, Toshiro Mizuno, Isao Tawara, (unknown), Tomoko Ogawa	6
8	P1-5 Retrospective analysis of the efficacy and safety of nivolumab in patients with treatment-refractory esophageal cancer 2021 ·Annals of Oncology ·Toshiaki Kobayashi, (unknown), (unknown), Akira Tsunoda, (unknown), Mikiya Ishihara, Kanako Saito, Yoshiki Yamashita, Toshiro Mizuno	0
9	P1-9 Retrospective analysis of the efficacy and safety of FOLFOX in patients with esophageal cancer 2021 ·Annals of Oncology ·(unknown), Akira Tsunoda, (unknown), (unknown), Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Yoshiki Yamashita, Toshiro Mizuno	0
10	CD204‑positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand‑1 expression 2020 ·Oncology Letters ·(unknown), Kanako Saito, Yuji Kozuka, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Makoto Ishitobi, (unknown), (unknown), Mikiya Ishihara, Toshiro Mizuno, Tomoko Ogawa, Naoyuki Katayama	10
11	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors 2020 ·Cancer Immunology Immunotherapy ·Mikiya Ishihara, (unknown), Yoshihiro Miyahara, Daisuke Muraoka, Naozumi Harada, Shinichi Kageyama, Takeshi Sasaki, (unknown), Norihito Soga, Katsunori Uchida, Taizo Shiraishi, Eiichi Sato, Hideki Kanda, Toshiro Mizuno, Gill Webster, Hiroaki Ikeda, Naoyuki Katayama, Yoshiki Sugimura, Hiroshi Shiku	21
12	MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours 2020 ·BMC Cancer ·Mikiya Ishihara, Shinichi Kageyama, Yoshihiro Miyahara, Takeshi Ishikawa, Shugo Ueda, Norihito Soga, Hiroaki Naota, Katsumi Mukai, Naozumi Harada, Hiroaki Ikeda, Hiroshi Shiku	33
13	First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer 2019 ·Case Reports in Oncology ·(unknown), Mikiya Ishihara, Yoshihiro Miyahara, Junko Nakamura, Yuji Kozuka, Motoh Iwasa, Akira Tsunoda, Yoshiki Yamashita, Kanako Saito, Toshiro Mizuno, Hiroshi Shiku, Naoyuki Katayama	30
14	Two cases of clinical tumor lysis syndrome following lapatinib in HER2 positive breast cancer 2015 ·Annals of Oncology ·(unknown), Mikiya Ishihara, Satoshi Tamaru, Yoshiki Yamashita, (unknown), (unknown), Yumiko Sugawara, Toshiro Mizuno, Naoyuki Katayama	1
15	Colon cancer chemotherapy for a patient with CDX2-expressing metastatic thymic adenocarcinoma: a case report and literature review 2015 ·International Cancer Conference Journal ·(unknown), Mikiya Ishihara, Yuji Kozuka, (unknown), Satoshi Tamaru, Yumiko Sugawara, Yoshiki Yamashita, Toshiro Mizuno, Taizo Shiraishi, Naoyuki Katayama	0
16	Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor 2014 ·PLoS ONE ·Mikiya Ishihara, Naohiro Seo, (unknown), Daisuke Muraoka, Maki Tanaka, Junichi Mineno, Hiroaki Ikeda, Hiroshi Shiku	12
17	Retrospective Analysis of Risk Factors for Central Nervous System Metastases in Operable Breast Cancer: Effects of Biologic Subtype and Ki67 Overexpression on Survival 2012 ·Oncology ·Mikiya Ishihara, Hirofumi Mukai, Shunji Nagai, Masakatsu Onozawa, Keiji Nihei, (unknown), Noriaki Wada	42
18	Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer 2009 ·International Journal of Clinical Oncology ·Mikiya Ishihara, Hirofumi Mukai, Shunji Nagai, Toru Mukohara	3
19	Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts 2003 ·International Journal of Oncology ·Mikiya Ishihara, Isao Tawara, Lijie Wang, Yoshiyuki Takahashi, Hiroshi Shiku	1
20	HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations 2002 ·Gene Therapy ·Katsumi Mukai, Yasuhiro Yasutomi, Masahiro Watanabe, Akira Kenjo, (unknown), (unknown), Hiroyoshi Nishikawa, Mikiya Ishihara, Teizo Fujita, Kagemasa Kuribayashi, Hiroshi Shiku	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact